Veno-venous ECLS rescue for a heart transplant recipient with COVID-19, a case report.
Hannah CopelandDavid A BaranJohn MortonVicente RodriguezEustace FernandesAsim MohammedPublished in: Perfusion (2023)
The potential for increased rates of morbidity of SARS-CoV-2 within immunocompromised populations has been of concern since the pandemic's onset. Transplant providers and patients can face particularly challenging situations, in the current settings as data continues to emerge for the prevention and treatment of the immunocompromised subpopulation. This case report details a patient 9-months post orthotopic heart transplant that developed SARS-CoV-2 infection despite two prior doses of the Pfizer-BioNtech COVID-19 vaccine, and had successful rescue from refractory hypoxemia with veno-venous extracorporeal membrane oxygenation (VV ECLS).
Keyphrases
- extracorporeal membrane oxygenation
- sars cov
- respiratory failure
- coronavirus disease
- acute respiratory distress syndrome
- respiratory syndrome coronavirus
- case report
- end stage renal disease
- heart failure
- ejection fraction
- newly diagnosed
- chronic kidney disease
- mechanical ventilation
- atrial fibrillation
- prognostic factors
- peritoneal dialysis
- climate change
- human health
- smoking cessation